Mexico Produces First Test Batch Of Russia’s Sputnik V Vaccine
MOSCOW — Mexico has produced the first test batch of the Russian Sputnik V Covid-19 vaccine at a local plant, said the Russian Direct Investment Fund.
Mexico has become the first country in North America to register Sputnik V and launch the local production of the Russian vaccine, as per the announcement by the Russian Direct Investment Fund and Mexican pharmaceutical company Laboratorios de Biologicos y Reactivos de Mexico.
“Production of the test batch is an important step in the technology transfer process, and we expect the batch to comply with the strictest requirements,” Kirill Dmitriev, chief executive of the Russian Direct Investment Fund, said.
“Sputnik V has been successfully used in Mexico for months, demonstrating excellent safety and efficacy profile. As Russian Direct Investment Fund and partners launch the local production of the vaccine, we strive to provide easier access to Sputnik V for the population of Mexico and help speed up the vaccination program.”
The vaccine produced in the North American country will be used in the national vaccination program.
As per the World Health Organization (WHO), there have 2,540,068 confirmed cases of Covid-19 with 233,622 deaths in Mexico. A total of 45,898,210 vaccine doses have been administered.
At present, Sputnik V has been registered in 67 countries globally, with a total population of over 3.5 billion people. The data obtained by regulators of several countries during the vaccination of the people, including Mexico, Argentina, Serbia, Bahrain, Hungary, UAE, and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
The release stated that Sputnik V is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in the course of vaccination, providing immunity with a longer duration than vaccines using the exact delivery mechanism for both shots.
Meanwhile, on WHO concern over Sputnik V coronavirus vaccine issues with the filling of vials at one plant, the Pharmastandard – UfaVITA said that the issues did not relate to the safety or efficacy of the vaccine itself; the plant is responsible only for pouring into vials doses of Sputnik V vaccine produced elsewhere.
“WHO did not raise any questions about the safety and efficacy of the produced and finished vaccine as the “Sputnik V” vaccine undergoes the strictest double quality output control of the Gamaleya Institute and the Russian health regulator (Federal Healthcare Service – Roszdravnadzor),” said Pharmstandard-UfaVITA.
Moreover, the WHO interim inspection did not identify any critical issues with the actual vaccine’s production, quality, clinical studies, possible side effects, or double quality output control by both the Gamaleya Institute and the Russian health regulator.
Instead, WHO inspectors’ attention was focused on only four technical issues mainly related to one of the filling lines that have all been subsequently fully addressed, said the statement.
Pharmstandard-UfaVITA invited WHO for another inspection.
(With inputs from ANI)
(Edited by Amrita Das and Saptak Datta. Map by Urvashi Makwana)